NovoCure (NVCR) Capital Expenditures (2014 - 2026)

NovoCure (NVCR) has reported Capital Expenditures for 13 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.

• Quarterly Capital Expenditures rose 26.07% year-over-year to $6.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.6 million (down 36.68% YoY) and the FY2025 annual result came in at $26.6 million, down 37.82% from the prior year.
• Capital Expenditures improved to $6.9 million in Q2 2026 per NVCR's latest filing, from $5.2 million in the prior quarter.
• Over the last five years, Capital Expenditures for NVCR reached as high as $11.8 million in Q1 2024 and fell as low as $4.1 million in Q2 2022.
• A 5-year average of $7.2 million and a median of $6.6 million in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures tumbled 54.95% — and 2024, when it surged 93.56%.
• Year by year, Capital Expenditures stood at $6.4 million in 2022, then rose by 6.06% to $6.8 million in 2023, then surged by 31.1% to $8.9 million in 2024, then slumped by 45.25% to $4.9 million in 2025, then surged by 41.26% to $6.9 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $6.9 million, $5.2 million, and $4.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.